MODY1 (HNF4A diabetes)

Overview

MODY1, or Maturity-Onset Diabetes of the Young type 1, is a rare form of monogenic diabetes. This means it is caused by a change in a single gene, rather than being multifactorial like type 1 or type 2 diabetes [PMID:33671215]. Unlike the more common forms of diabetes, MODY1 typically has an autosomal dominant inheritance pattern, meaning it often affects multiple generations within a family. Individuals with MODY1 usually develop diabetes before the age of 25, even if they have a healthy weight and lifestyle, which can sometimes lead to misdiagnosis as type 1 or type 2 diabetes.

The condition arises from changes in the HNF4A gene, which plays a crucial role in the development and function of the pancreas. The pancreas is responsible for producing insulin, a hormone vital for regulating blood sugar levels. When the HNF4A gene doesn't work correctly, the pancreas may not produce enough insulin, or the insulin it produces may not be as effective, leading to high blood glucose.

Recognising MODY1 is important because the management approach can differ significantly from other types of diabetes. A correct diagnosis can lead to more personalised and effective treatment, often involving specific types of medication that may not be used for type 1 or type 2 diabetes. While exact prevalence is not well established, it is considered a rare condition within the broader spectrum of diabetes.

Symptoms & clinical features

The symptoms of MODY1 are similar to those of other forms of diabetes, primarily related to high blood glucose levels. These can include increased thirst, frequent urination, unexplained weight loss, and fatigue. Some individuals may also experience blurred vision or recurrent infections.

Notably, the onset of symptoms for MODY1 often occurs during adolescence or early adulthood, typically before the age of 25, but it can sometimes present in infancy [PMID:30138986]. In some cases, individuals may experience mild symptoms or have elevated blood glucose levels detected incidentally during routine medical checks, without significant symptoms. Due to the genetic nature of MODY1, there is often a strong family history of diabetes, with multiple relatives affected across different generations.

Babies born to mothers with MODY1 may sometimes have a higher birth weight, a condition known as macrosomia, even if the mother's diabetes is well-controlled during pregnancy [PMID:33671215]. This is thought to be due to the HNF4A gene's role in foetal development and glucose metabolism. Recognising this early sign can sometimes provide a clue for later diagnosis in the child.

Video: Genetics 101

Affected organs

MODY1 primarily affects the pancreas, specifically the beta cells within the pancreas. These cells are responsible for producing and releasing insulin, the hormone that helps regulate blood glucose levels. When the HNF4A gene is altered, the beta cells may not develop or function as effectively as they should, leading to insufficient insulin production.

While the primary impact is on the pancreas and glucose regulation, the HNF4A gene also plays a role in the liver and kidneys. However, the direct clinical consequences of MODY1 are predominantly related to the altered pancreatic function and subsequent issues with blood glucose control. Long-term, poorly controlled blood glucose, regardless of the type of diabetes, can affect various organ systems, including the eyes, kidneys, nerves, and heart. Early and accurate diagnosis of MODY1 allows for appropriate management, which can help prevent or delay these potential long-term complications.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

The severity of MODY1 can vary between individuals, even within the same family. Some people might experience relatively mild symptoms and require less intensive management, while others may have more significant insulin deficiency and require stricter control of their blood glucose levels. Generally, MODY1 is characterised by a progressive decline in insulin secretion over time.

Individuals with MODY1 have a lifelong risk of elevated blood glucose levels. If left unmanaged, chronically high blood glucose can lead to long-term complications typical of other forms of diabetes, such as damage to the eyes (retinopathy), kidneys (nephropathy), nerves (neuropathy), and an increased risk of cardiovascular disease. However, with an accurate diagnosis and appropriate management, many of these complications can be prevented or significantly delayed.

Age of onset is typically before 25 years, often in adolescence or early adulthood. While some individuals may develop symptoms in infancy, this is less common. The condition does not generally lead to ketoacidosis at diagnosis, which is a common and serious complication at the onset of type 1 diabetes.

Genetic causes

MODY1 is caused by pathogenic variants in the HNF4A gene (hepatocyte nuclear factor 4 alpha). This gene provides instructions for making a protein that acts as a 'master regulator' for many other genes, especially those involved in the development and function of the pancreas and liver. The HNF4A protein is a transcription factor, meaning it controls when other genes are turned on or off.

Specifically, the HNF4A protein plays a critical role in the beta cells of the pancreas, which are responsible for producing insulin. It helps regulate genes essential for the production, storage, and secretion of insulin. When a change in the HNF4A gene occurs, the resulting protein may not function correctly, leading to impaired beta-cell function. This can result in the pancreatic beta cells producing insufficient amounts of insulin, or producing insulin that is less effective at regulating blood sugar [PMID:30138986].

Identifying a pathogenic variant in HNF4A is key to confirming a diagnosis of MODY1. This genetic information not only helps differentiate MODY1 from other types of diabetes but also guides treatment decisions, as individuals with MODY1 often respond well to specific oral medications.

• HNF4A
  hepatocyte nuclear factor 4 alpha
  The HNF4A gene provides instructions for producing the Hepatocyte Nuclear Factor 4 Alpha protein, a key transcription factor involved in regulating gene expression vital for pancreatic beta cell function and liver metabolism.

Inheritance pattern

MODY1 has an autosomal dominant inheritance pattern. This means that a person only needs to inherit one copy of the altered HNF4A gene from one parent to develop the condition. If a parent has MODY1, there is a 50% chance that each of their children will inherit the altered gene and therefore be affected.

The condition typically runs in families, often appearing in every generation. However, in some rare cases, a new (de novo) pathogenic variant in the HNF4A gene can occur in an individual for the first time, with no family history of the condition. In such instances, the affected individual would then have a 50% chance of passing the altered gene to each of their children.

Family members of someone diagnosed with MODY1, particularly first-degree relatives like parents, siblings, and children, may be offered genetic testing to determine if they also carry the altered gene. This allows for early diagnosis and appropriate management or surveillance, even if symptoms have not yet developed.

Diagnosis & testing

The diagnosis of MODY1 is typically suspected based on clinical features, such as diabetes diagnosed before age 25, a strong family history of diabetes across multiple generations, and the absence of features typical of type 1 or type 2 diabetes. However, a definitive diagnosis requires genetic testing.

Genetic testing for MODY1 involves a blood or saliva sample to analyse the HNF4A gene. This testing looks for specific pathogenic variants that are known to cause the condition. In the UK, genetic testing for monogenic diabetes, including MODY1, is typically initiated by a specialist paediatrician or endocrinologist and is available through the NHS Genomic Medicine Service (GMS) pathways. The relevant NHS National Genomic Test Directory R-code for monogenic diabetes is R180. Patients usually need a referral to a clinical genetics service or a specialist diabetes clinic for this testing.

Confirmation of a genetic diagnosis is crucial because it can significantly impact treatment choices and allows for genetic counselling and testing for at-risk family members. Sometimes, specific clinical criteria, such as particular levels of C-peptide (a marker of insulin production) or autoantibodies (which are usually absent in MODY1), can help guide the decision to pursue genetic testing.

Management & lifestyle

The management of MODY1 focuses on maintaining stable blood glucose levels to prevent symptoms and long-term complications. Unlike type 1 diabetes, where insulin injections are usually essential from diagnosis, individuals with MODY1 often respond very well to sulphonylurea medications, which are oral tablets [PMID:30138986]. These drugs work by stimulating the pancreas to produce more insulin.

In some cases, especially as the condition progresses over many years, insulin therapy may eventually be required. Regular monitoring of blood glucose levels is a cornerstone of management, along with routine check-ups to screen for potential diabetes complications affecting the eyes, kidneys, and feet. Lifestyle measures, such as a balanced diet and regular physical activity, are also encouraged to support overall health and blood glucose control.

Individuals diagnosed with MODY1, or those at risk, should be referred to specialist diabetes clinics within the NHS. Genetic counsellors can provide essential support and information regarding the inheritance pattern, implications for family members, and assist with family testing. Management plans are individualised and should always be discussed with a healthcare team.

UK care pathway

In the UK, if MODY1 is suspected, individuals are typically referred by their GP or existing diabetes team to a specialist paediatric or adult endocrinology service. From there, if monogenic diabetes is strongly considered, a referral will be made to a clinical genetics service or specialist centre for definitive diagnosis through genetic testing. Genetic testing for monogenic diabetes, including MODY1, is covered by the NHS National Genomic Test Directory under relevant R-codes, such as R180 for monogenic diabetes.

Following a genetic diagnosis, individuals will be supported by a multidisciplinary team, which may include endocrinologists, specialist nurses, dietitians, and genetic counsellors. Genetic counsellors play a vital role in explaining the inheritance pattern, discussing the implications for family members, and arranging cascade testing for at-risk relatives. This integrated approach ensures that patients and their families receive comprehensive care and information.

Related conditions

MODY1 is one of several types of Maturity-Onset Diabetes of the Young (MODY), all of which are monogenic forms of diabetes. Other common types include MODY2 (GCK diabetes, caused by variants in the GCK gene) and MODY3 (HNF1A diabetes, caused by variants in the HNF1A gene). While all MODY types share features like early onset and autosomal dominant inheritance, they differ in their genetic cause, clinical presentation, and optimal treatment strategies.

For example, MODY2 often presents with milder, non-progressive hyperglycaemia and typically requires no medication, distinguishing it from MODY1 which often requires treatment. MODY3, like MODY1, usually responds well to sulphonylureas, but may have a slightly different progression and risk of complications. Differentiating between these MODY types is crucial for guiding appropriate medical management and providing accurate prognostic information.

Frequently asked questions